Company Overview of ARCA biopharma, Inc.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. The company has a collaboration agreement with Medtronic, Inc. for the support of Gencaro’s Phase IIB/III clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
11080 CirclePoint Road
Westminster, CO 80020
Key Executives for ARCA biopharma, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $300.7K
Senior Vice President, General Counsel and Secretary
Total Annual Compensation: $285.6K
Compensation as of Fiscal Year 2014.
ARCA biopharma, Inc. Key Developments
ARCA biopharma, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 11 15
ARCA biopharma, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $2,719,000 against $2,406,000 a year ago. Net loss and comprehensive loss was $2,719,000 or $0.10 per basic and diluted share against $2,405,000 or $0.11 per basic and diluted share a year ago.
For the six months, the company reported loss from operations of $5,463,000 against $4,796,000 a year ago. Net loss and comprehensive loss was $5,463,000 or $0.22 per basic and diluted share against $4,794,000 or $0.24 per basic and diluted share a year ago.
ARCA biopharma, Inc. Regains Compliance With Minimum Bid Price Rule Of The NASDAQ Capital Market
Jul 16 15
On July 15, 2015, The Nasdaq Stock Market, notified ARCA biopharma, Inc. that the company had regained compliance with the applicable minimum bid price rule of The NASDAQ Capital Market as set forth in NASDAQ Rule 5550(a)(2). Accordingly, the previous notice received by the company on February 18, 2015 is now closed. On June 22, 2015, the company’s stockholders authorized the company’s Board of Directors for a period of up to one year, to effect a reverse split of the company’s common stock. Although the company has regained compliance with the Nasdaq listing standards, the company’s Board may still elect to proceed with the reverse split if, in the Board’s judgment, it is considered to be in the best interest of the company’s stockholders.
ARCA biopharma, Inc. Proposes Amendments to the Restated Certificate of Incorporation
Apr 14 15
ARCA biopharma, Inc. proposed to approve amendments to the Company’s restated certificate of incorporation, as amended, and authorize the Board of Directors, if in their judgment it is necessary, to select and file one such amendment to effect a reverse stock split of common stock, at a ratio in the range of 3:1 to 20:1, such ratio to be determined at the discretion of the Board of Directors, to it's annual general meeting to be held on June 04, 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 10, 2015